On November 14, 2016, Asterias Biotherapeutics, Inc. (the
Company) announced via press release certain operating and
financial results for the quarter ended September 30, 2016. A
copy of the Companys press release is attached hereto as Exhibit
99.1.

Also on November 14, 2016, the Company held a conference call
with analysts and investors, the transcript is filed as Exhibit
99.2 hereto and is incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the
information in Item 2.02 of this Current Report on Form 8-K,
including Exhibits 99.1 and 99.2, shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the liability
of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933, as amended, or
the Exchange Act, except as expressly set forth by specific
reference in such a filing.

Item 9.01

Financial Tables and Exhibits.

(d)

Exhibits.